Related Experiment Video
Updated: Apr 5, 2026

09:47
Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
2.0K
Discriminative multi-task feature selection for multi-modality classification of Alzheimer's disease
Tingting Ye1, Chen Zu1, Biao Jie1
1School of Computer Science and Technology, Nanjing University of Aeronautics and Astronautics, Nanjing, 210016, China.
Brain Imaging and Behavior
|August 28, 2015
Summary
This study introduces a new feature selection method for classifying Alzheimer's disease (AD) and mild cognitive impairment (MCI) using multi-modality data. The approach enhances classification accuracy by better utilizing discriminative information among subjects.
Area of Science:
- Neuroimaging
- Machine Learning
- Biomedical Data Analysis
Background:
- Multi-task feature selection is applied to classify Alzheimer's disease (AD) and mild cognitive impairment (MCI) using multi-modality data.
- Traditional methods often fail to fully exploit discriminative subject information, limiting classification performance.
Purpose of the Study:
- To propose a novel discriminative multi-task feature selection method for improved AD/MCI classification.
- To enhance the mining of discriminative information across multiple data modalities.
Main Methods:
- A linear regression model is trained for each modality, with group-sparsity regularization for joint feature selection.
- A discriminative regularization term using intra-class and inter-class Laplacian matrices is introduced.
- The method was evaluated on 202 subjects (AD, MCI, healthy controls) using MRI and FDG-PET data from ADNI.
Main Results:
- The proposed method significantly improved classification performance for AD/MCI.
- It demonstrated potential in discovering disease-related biomarkers for diagnosis.
- Performance was compared favorably against several state-of-the-art methods.
Conclusions:
- The discriminative multi-task feature selection method offers superior performance in multi-modality AD/MCI classification.
- The approach effectively leverages discriminative subject information and identifies potential biomarkers.
- This method advances the field of neuroimaging-based disease diagnosis.
Related Concept Videos
Alzheimer's Disease: Overview
2.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Alzheimer's Disease: Treatment
1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K

